3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
9
Neoplasms
6
Neoplasm Metastasis
5
Carcinoma
5
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Skin Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Noonan Syndrome
1
Non Small Cell Lung Cancer Metastatic
1
Neoplasms, Squamous Cell
1
Neoplasms by Site
1
NSCLC
1
Multiple Myeloma
1
Lymphoma
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR T790M+ NSCLC
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Interventions
Rituximab
4
blinatumomab
3
Whole-Body Irradiation
3
Cyclophosphamide
3
fludarabine phosphate
2
Mycophenolic Acid
2
Melphalan
2
Lenalidomide
2
Clofarabine
2
treosulfan
1
thymoglobulin
1
sabatolimab
1
pembrolizumab
1
peginterferon alfa-2a
1
obinutuzumab
1
midostaurin
1
ixazomib
1
fludarabine
1
eribulin
1
daratumumab
1
acalabrutinib
1
Trastuzumab
1
Tacrolimus
1
Sodium Chloride
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pentostatin
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Methotrexate
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Neoplasm, Residual
×
osimertinib
×
Clear all
No trials found.